** Shares of medical device maker NeuroPace NPCE.O fall 15% to $15.02 premarket
** Co, citing preliminary data, says neuromodulation therapy for a group of genetic epilepsy syndromes failed to meet main efficacy goal in the overall population in a 2-year study
** The device, RNS System, is implanted in the skull to constantly monitor brain waves, identifying and disrupting unusual activity that may trigger seizures
** The device, however, showed significant efficacy in a subset of patients, which represents the majority of participants - NPCE
** It is approved in the U.S. to treat focal epilepsy, a type of seizure that affects only one side of the brain and body
** Up to last close, stock up ~58% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.